Summary of results for purine analogs based therapy in patients with LGL leukemia
| No. of patients . | Treatment . | ORR . | Duration of response (mo) . | Comments . | Reference (year) . |
|---|---|---|---|---|---|
| 1 | 2CDA | 1/1 (after 2 courses) | — | — | 76 (1997) |
| 1 | F | 1/1 | — | — | 77 (2003) |
| 1 | DCF | 1/1 | > 12 | — | 78 (2003) |
| 9 | FND | 9/9 | 13-35 | 8 patients had PRCA; 7 MR | 79 (2004) |
| 4 | DCF | 3/4 | — | — | 65 (2006) |
| 3 | FND | 3/3 | 12-40 | 2 MR | 80 (2007) |
| 2 | DCF/A | 0/2 | Toxic; | 75 (2007) | |
| 1 | DCF | 1/1 | > 13 | no MR | 81 (2008) |
| 9 | DCF | 7/9 | 3 | Time to treatment failure 7-10 mo | 69 (2010) |
| 4 | DCF | 3/4 | — | Complications: 1 case of AIHA | 12 (2010) |
| 3 | F | 1/3 | > 28 | — | 82 (2010) |
| Total n = 38 | 30/38 (79%) | — | — |
| No. of patients . | Treatment . | ORR . | Duration of response (mo) . | Comments . | Reference (year) . |
|---|---|---|---|---|---|
| 1 | 2CDA | 1/1 (after 2 courses) | — | — | 76 (1997) |
| 1 | F | 1/1 | — | — | 77 (2003) |
| 1 | DCF | 1/1 | > 12 | — | 78 (2003) |
| 9 | FND | 9/9 | 13-35 | 8 patients had PRCA; 7 MR | 79 (2004) |
| 4 | DCF | 3/4 | — | — | 65 (2006) |
| 3 | FND | 3/3 | 12-40 | 2 MR | 80 (2007) |
| 2 | DCF/A | 0/2 | Toxic; | 75 (2007) | |
| 1 | DCF | 1/1 | > 13 | no MR | 81 (2008) |
| 9 | DCF | 7/9 | 3 | Time to treatment failure 7-10 mo | 69 (2010) |
| 4 | DCF | 3/4 | — | Complications: 1 case of AIHA | 12 (2010) |
| 3 | F | 1/3 | > 28 | — | 82 (2010) |
| Total n = 38 | 30/38 (79%) | — | — |
ORR indicates overall response rate; 2CDA, 2-chlorodeoxyadenosine: F, fludarabine; DCF, deoxycoformycine; FND, fludarabine-mitoxantrone-dexamethasone; —, not applicable; PRCA, pure cell aplasia; MR, molecular response; and AIHA, autoimmune hemolytic anemia.